Favorable Outcome of Intensive Treatment for Relapsed Diffuse Large B Cell Lymphoma With Secondary Central Nervous System Involvement
Anticancer Research · 2026
DOI: 10.21873/anticanres.18416 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Hung Chang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Chang Gung Memorial Hospital, Linkou, Taiwan, R.O.C.; horng@adm.cgmh.org.tw. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology, Chang Gung Memorial Hospital, Linkou, Taiwan, R.O.C.; horng@adm.cgmh.org.tw.
- School of Medicine, Chang Gung University, Taoyuan, Taiwan, R.O.C.
- College of Life Science and Medicine, National Tsing Hua University, Hsinchu, Taiwan, R.O.C.
- Division of Hematology, Chang Gung Memorial Hospital, Linkou, Taiwan, R.O.C.
- Depatement of Internal Medicine, Chang Gung Memorial Hospital, Tucheng, Taiwan, R.O.C.
Zitieren
APA
Chang, H., Kuo, M. C., Ou, C. W., Kao, H. W., Lin, T. L., Hung, Y. S., Shih, H. J., & Ong, Y. C. (2026). Favorable Outcome of Intensive Treatment for Relapsed Diffuse Large B Cell Lymphoma With Secondary Central Nervous System Involvement. Anticancer Research. https://doi.org/10.21873/anticanres.18416
Vancouver
Chang H, Kuo MC, Ou CW, Kao HW, Lin TL, Hung YS, et al. Favorable Outcome of Intensive Treatment for Relapsed Diffuse Large B Cell Lymphoma With Secondary Central Nervous System Involvement. Anticancer Research. 2026. doi:10.21873/anticanres.18416
BibTeX
@article{Chang2026,
author = {Chang, Hung and Kuo, Ming-Chung and Ou, Che-Wei and Kao, Hsiao-Wen and Lin, Tung-Liang and Hung, Yu-Shin and Shih, Hsuan-Jen and Ong, Yuen-Chin},
title = {Favorable Outcome of Intensive Treatment for Relapsed Diffuse Large B Cell Lymphoma With Secondary Central Nervous System Involvement},
journal = {Anticancer Research},
year = {2026},
doi = {10.21873/anticanres.18416}
}
EUVIMED